日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

阿特珠单抗治疗高危局部晚期头颈部鳞状细胞癌：一项随机临床试验

期刊:Journal of the American Medical Association
影响因子:55
doi:10.1001/jama.2025.1483
Haddad, Robert; Fayette, Jérôme; Teixeira, Maria; Prabhash, Kumar; Mesia, Ricard; Kawecki, Andrzej; Dechaphunkul, Arunee; Dinis, José; Guo, Ye; Masuda, Muneyuki; Hsieh, Ching-Yun; Ghi, Maria Grazia; Vaz de Melo Sette, Claudia; Harrington, Kevin; Tahara, Makoto; Saba, Nabil F; Lau, Agnes; Jiang, Tao; Yan, Yibing; Ballinger, Marcus; Kaul, Monika; Matheny, Christina; Cuchelkar, Vaikunth; Wong, Deborah J
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Association Between Epstein-Barr Virus Infection and PD-L1 Expression in Gastric Cancer: Prevalence, Clinicopathological Features, and Prognostic Implications

Epstein-Barr病毒感染与胃癌中PD-L1表达的相关性：患病率、临床病理特征和预后意义

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17091492
Wonglhow, Jirapat; Tantipisit, Jarukit; Wetwittayakhlang, Panu; Sunpaweravong, Patrapim; Sathitruangsak, Chirawadee; Kanjanapradit, Kanet; Thongwatchara, Phatcharaporn; Dechaphunkul, Arunee
胃癌
肿瘤
肿瘤免疫
炎症/感染
微生物学
PD-L1
发表日期：2025
文献求助 收藏

Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study

HER2低表达与HER2零表达的HR阳性转移性乳腺癌患者接受内分泌治疗（联合或不联合CDK4/6抑制剂）的临床结局：一项多中心回顾性研究

期刊:International Journal of Breast Cancer
影响因子:3
doi:10.1155/ijbc/5597051
Susiriwatananont, Thiti; Wongkraisri, Concord; Dajsakdipon, Thanate; Supavavej, Archara; Dechaphunkul, Arunee; Sunpaweravong, Patrapim; Neesanun, Sunee; Ithimakin, Suthinee; Dejthevaporn, Thitiya; Parinyanitikul, Napa
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Role of Adjuvant Chemotherapy in Resected Small Bowel Adenocarcinoma: An Exploratory Real-World Analysis of Survival Outcomes and Prognostic Factors

辅助化疗在切除小肠腺癌中的作用：生存结果和预后因素的探索性真实世界分析

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm14217513
Wonglhow, Jirapat; Sunpaweravong, Patrapim; Sathitruangsak, Chirawadee; Dechaphunkul, Arunee; Wetwittayakhlang, Panu
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A 20-Year Real-World Study of Small Bowel Cancers: Histologic Subtypes, Clinical Features, and Survival Implications

一项为期 20 年的小肠癌真实世界研究：组织学亚型、临床特征和生存意义

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm14196962
Wonglhow, Jirapat; Sunpaweravong, Patrapim; Sathitruangsak, Chirawadee; Dechaphunkul, Arunee; Wetwittayakhlang, Panu
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Trends in Cancer Diagnoses Among People Living with HIV: A 20-Year Retrospective Study from a Tertiary Center in Thailand

泰国一家三级医疗中心20年回顾性研究：艾滋病毒感染者癌症诊断趋势

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm15010022
Wonglhow, Jirapat; Chaiwiriyawong, Supakorn; Sunpaweravong, Patrapim; Sathitruangsak, Chirawadee; Dechaphunkul, Arunee
肿瘤
肿瘤免疫
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

Effectiveness of Palliative Chemotherapy and Associated Prognostic Factors in Advanced Small Bowel Adenocarcinoma: A Propensity Score-Matched Analysis

姑息性化疗对晚期小肠腺癌疗效及相关预后因素的影响：倾向评分匹配分析

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S558642
Wonglhow, Jirapat; Dechaphunkul, Arunee; Sathitruangsak, Chirawadee; Sunpaweravong, Patrapim; Wetwittayakhlang, Panu
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

研究总结：奥希替尼治疗EGFR突变型非小细胞肺癌切除术后患者的总生存期

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-024-01034-3
Tsuboi, Masahiro; Herbst, Roy S; John, Thomas; Kato, Terufumi; Majem, Margarita; Grohé, Christian; Wang, Jie; Goldman, Jonathan W; Lu, Shun; de Marinis, Filippo; Shepherd, Frances A; Lee, Ki Hyeong; Le, Nhieu Thi; Dechaphunkul, Arunee; Kowalski, Dariusz; Bonanno, Laura; Dómine, Manuel; Poole, Lynne; Bolanos, Ana; Rukazenkov, Yuri; Wu, Yi-Long
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2024
文献求助 收藏

LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study

LABS评分——FOLFOX4治疗晚期肝细胞癌的预后工具及其真实世界疗效：一项单中心回顾性研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12040-z
Wonglhow, Jirapat; Sunpaweravong, Patrapim; Sathitruangsak, Chirawadee; Dechaphunkul, Arunee
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

比较帕博西尼或瑞博西尼联合AI治疗HR+/HER2-晚期乳腺癌患者的生存疗效（CEPRA研究）：来自泰国的真实世界数据的初步分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12765-x
Dajsakdipon, Thanate; Susiriwatananont, Thiti; Wongkraisri, Concord; Ithimakin, Suthinee; Parinyanitikul, Napa; Supavavej, Archara; Dechaphunkul, Arunee; Sunpaweravong, Patrapim; Neesanun, Sunee; Akewanlop, Charuwan; Dejthevaporn, Thitiya
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏